Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Inventory (2021 - 2025)

Apellis Pharmaceuticals (APLS) has 5 years of Inventory data on record, last reported at $142.6 million in Q4 2025.

  • For Q4 2025, Inventory rose 75.12% year-over-year to $142.6 million; the TTM value through Dec 2025 reached $142.6 million, up 75.12%, while the annual FY2025 figure was $142.6 million, 75.12% up from the prior year.
  • Inventory reached $142.6 million in Q4 2025 per APLS's latest filing, up from $122.8 million in the prior quarter.
  • Across five years, Inventory topped out at $161.3 million in Q1 2024 and bottomed at $1.7 million in Q3 2021.
  • Average Inventory over 5 years is $87.8 million, with a median of $85.7 million recorded in 2022.
  • Peak YoY movement for Inventory: skyrocketed 3463.09% in 2022, then tumbled 48.87% in 2025.
  • A 5-year view of Inventory shows it stood at $16.3 million in 2021, then surged by 426.3% to $85.7 million in 2022, then soared by 70.76% to $146.4 million in 2023, then tumbled by 44.38% to $81.4 million in 2024, then soared by 75.12% to $142.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $142.6 million in Q4 2025, $122.8 million in Q3 2025, and $121.0 million in Q2 2025.